Robert Falotico
48Patents
11h-index
34Co-inventors
75Inventor score
Filing activity: Sep 29, 1983 → Jun 6, 2014
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8273404B2 | Extraction of solvents from drug containing polymer reservoirs | Human Necessities | 1,338 | Active |
| US6776796B2 | Antiinflammatory drug and delivery device | Human Necessities | 184 | Expired |
| US7195640B2 | Coated medical devices for the treatment of vulnerable plaque | Human Necessities | 115 | Expired |
| US7419678B2 | Coated medical devices for the prevention and treatment of vascular disease | Human Necessities | 60 | Expired |
| US7223286B2 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent | Human Necessities | 51 | Expired |
| US7229473B2 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent | Human Necessities | 43 | Active |
| US7217286B2 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent | Human Necessities | 42 | Active |
| US4822800A | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties | Chemistry; Metallurgy | 29 | Expired |
| US7300662B2 | Drug/drug delivery systems for the prevention and treatment of vascular disease | Human Necessities | 26 | Expired |
| US7303758B2 | Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury | Human Necessities | 20 | Expired |
| US8784860B2 | Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease | Human Necessities | 12 | Active |
| US7591844B2 | Medical devices, drug coatings and methods for maintaining the drug coatings thereon | Emerging Cross-Sectional Technologies | 10 | Active |
| US4672116A | Substituted 5,6-dialkoxyquinazoline derivatives | Human Necessities | 10 | Expired |
| US4711883A | Substituted 3-(4-phenyl-1-piperazinyl)alkylquinazolin-2,4-(1H,3H) diones, methods of preparation, compositions and method of use | Human Necessities | 10 | Expired |
| US7947302B2 | Antithrombotic coating for drug eluting medical devices | Human Necessities | 8 | Active |
| US8506984B2 | Therapeutic agent elution control process | Human Necessities | 6 | Active |
| US5030736A | Substituted thienopyrans | Chemistry; Metallurgy | 5 | Expired |
| US8029561B1 | Drug combination useful for prevention of restenosis | Human Necessities | 5 | Expired |
| US7806924B2 | Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis | Human Necessities | 5 | Active |
| US4963554A | 6,7-dimethoxy-1,2-dihydro-2-arylquinazoline-3-oxides | Chemistry; Metallurgy | 4 | Expired |
| US10029034B2 | Drug-eluting articles with improved drug release profiles | Human Necessities | 4 | Active |
| US5284857A | Substituted thienopyrans as antihypertensive agents | Human Necessities | 4 | Expired |
| US7875282B2 | Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury | Human Necessities | 3 | Active |
| US4639518A | Substituted quinazolinediones | Chemistry; Metallurgy | 3 | Expired |
| US7695731B2 | Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury | Human Necessities | 3 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.